TPI Receives SFDA Approval for Its Anti-Diabetic Drug Gliclazide

Friday, May 13, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

For more information, please contact:

James Jiayuan Tong M.D. Ph.D.

Chief Financial Officer, Chief Business & Development Officer

Director

Tianyin Pharmaceutical Co., Inc.

Web: http://www.tianyinpharma.com

Email: [email protected]

Tel: +86-28-8551-6696 (Chengdu, China)

+86-134-3655-0011 (China)

+1-949-350-6999 (U.S.)

Address: 23rd Floor, Unionsun Yangkuo Plaza

No. 2, Block 3, South Renmin Road

Chengdu, 610041

China



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook